FDA Drug · D-0673-2026

Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous or Subcutaneous Use, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873. NDC: 70069-0836-01

Class II · Ongoing

Lack of Sterility Assurance

Affected lots / codes — check yours against thisLot, expiry: RBIH0125A Jan 31, 2028; RBIH0225A Feb 29, 2028; RBIH0325A Feb 29, 2028; RBIH0525A Mar 31, 2028

Recalling firm: Reliance Life Sciences Private Limited, Navi Mumbai, N/A
Classification: Class II (temporary or reversible harm possible)
Status: Ongoing
Quantity: 11,400 vials
Distribution: Nationwide in the USA
Recall initiated: June 24, 2026
Classified: July 8, 2026
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0673-2026%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →